Risk of recurrent stroke and antiplatelet choice in breakthrough stroke while on aspirin
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Joon-Tae | - |
dc.contributor.author | Kim, Beom Joon | - |
dc.contributor.author | Park, Jong-Moo | - |
dc.contributor.author | Lee, Soo Joo | - |
dc.contributor.author | Cha, Jae-Kwan | - |
dc.contributor.author | Park, Tai Hwan | - |
dc.contributor.author | Lee, Kyung Bok | - |
dc.contributor.author | Lee, Jun | - |
dc.contributor.author | Hong, Keun-Sik | - |
dc.contributor.author | Lee, Byung-Chul | - |
dc.contributor.author | Kim, Dong-Eog | - |
dc.contributor.author | Choi, Jay Chol | - |
dc.contributor.author | Kwon, Jee-Hyun | - |
dc.contributor.author | Shin, Dong-Ick | - |
dc.contributor.author | Sohn, Sung Il | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Bae, Hee-Joon | - |
dc.date.accessioned | 2021-08-30T11:14:26Z | - |
dc.date.available | 2021-08-30T11:14:26Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-10-07 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/52480 | - |
dc.description.abstract | Uncertainty regarding an optimal antiplatelet regimen still exists in patients with breakthrough acute ischemic stroke (AIS) while on aspirin. This study provides an analysis of a prospective multicenter registry between April 2008 and April 2014. Eligible patients were on aspirin at the time of AIS and treated with antiplatelet regimens (aspirin, clopidogrel, or clopidogrel-aspirin). Potential factors associated with the choice of each antiplatelet regimen were explored and included a predictive risk score for future vascular events, the Essen Stroke Risk Score (ESRS). A total of 2348 patients (age, 69 +/- 11 years; male, 57.7%) were analyzed, and 55.3%, 25.3% and 19.4% were treated with clopidogrel-aspirin, aspirin and clopidogrel, respectively. While the likelihood of choosing clopidogrel-aspirin increased as the ESRS increased, the likelihood of choosing aspirin decreased as the ESRS increased (P-trend<0.001). The ESRS category (0-1/2-3/>= 4) modified the effect of antiplatelet regimens for 1-year vascular events (P-interaction<0.01). Among patients with ESRS >= 4, clopidogrel-aspirin (HR 0.47 [0.30-0.74]) and clopidogrel (HR 0.30 [0.15-0.60]) significantly reduced the risk of outcome events. Our study showed that more than half of the patients with aspirin failure were treated with clopidogrel-aspirin. In particular, a higher ESRS, which indicates an increased risk of recurrent stroke, was associated with the choice of clopidogrel-aspirin rather than aspirin. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE RESEARCH | - |
dc.subject | ACUTE ISCHEMIC-STROKE | - |
dc.subject | CLOPIDOGREL | - |
dc.subject | THERAPY | - |
dc.subject | ATTACK | - |
dc.subject | MANAGEMENT | - |
dc.subject | BENEFIT | - |
dc.subject | DEATH | - |
dc.subject | SCORE | - |
dc.title | Risk of recurrent stroke and antiplatelet choice in breakthrough stroke while on aspirin | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Juneyoung | - |
dc.identifier.doi | 10.1038/s41598-020-73836-0 | - |
dc.identifier.scopusid | 2-s2.0-85092155151 | - |
dc.identifier.wosid | 000577451900002 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.10, no.1 | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | ACUTE ISCHEMIC-STROKE | - |
dc.subject.keywordPlus | CLOPIDOGREL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | ATTACK | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | BENEFIT | - |
dc.subject.keywordPlus | DEATH | - |
dc.subject.keywordPlus | SCORE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.